Please use this identifier to cite or link to this item:
|Title:||Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.|
|Authors:||Van Cutsem, Eric;Eng, Cathy;Nowara, Elzbieta;Swieboda-Sadlej, Anna;Tebbutt, Niall C;Mitchell, Edith;Davidenko, Irina;Stephenson, Joe;Elez, Elena;Prenen, Hans;Deng, Hongjie;Tang, Rui;McCaffery, Ian;Oliner, Kelly S;Chen, Lisa;Gansert, Jennifer;Loh, Elwyn;Smethurst, Dominic;Tabernero, Josep|
|Affiliation:||Austin Health, Heidelberg, VIC, Australia|
University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium
Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
University of Texas M.D. Anderson Cancer Center, Houston, Texas;
Instytut im. M. Sklodowskiej-Curie, Gliwice;
Warszawski Uniwersytet Medyczny, Warszawa, Poland;
Thomas Jefferson University, Philadelphia, Pennsylvania;
Krasnodar City Oncology Center, Krasnodar, Russia;
Cancer Centers of the Carolinas, Greenville, South Carolina;
Amgen Inc., ThoUSAnd Oaks;
Amgen Inc., South San Francisco, California;
Amgen Ltd., London, United Kingdom.
|Citation:||Clinical Cancer Research : An Official Journal of the American Association For Cancer Research 2014; 20(16): 4240-50|
|Abstract:||Panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody (mAb), has demonstrated efficacy in patients with wild-type KRAS metastatic colorectal cancer (mCRC). Rilotumumab and ganitumab are investigational, fully human mAbs against hepatocyte growth factor (HGF)/scatter factor and IGF1R, respectively. Here we evaluate combining rilotumumab or ganitumab with panitumumab in previously treated patients with wild-type KRAS mCRC.Part 1 was a phase Ib dose-finding study of panitumumab plus rilotumumab. The primary endpoint was the incidence of dose-limiting toxicities (DLT). Part 2 was a randomized phase II trial of panitumumab in combination with rilotumumab, ganitumab, or placebo. The primary endpoint was objective response rate (ORR); safety, progression-free survival (PFS), and overall survival (OS) were secondary endpoints. Archival tissue specimens were collected for exploratory correlative work.In part 1, no DLTs were reported. A recommended phase II dose of 10 mg/kg rilotumumab was selected. In part 2, for the panitumumab plus rilotumumab (n = 48), panitumumab plus ganitumab (n = 46), and panitumumab plus placebo arms (n = 48), the ORRs were 31%, 22%, and 21%, respectively. The median PFS was 5.2, 5.3, and 3.7 months and median OS 13.8, 10.6, and 11.6 months, respectively. Adverse events were tolerable. Exploratory biomarker analyses, including MET and IGF-related protein expression, failed to indicate conclusive predictive evidence on efficacy endpoints.Panitumumab plus rilotumumab met the prespecified criterion for improvement in ORR whereas ganitumab did not. This is the first study to suggest a benefit for combining an HGF inhibitor (rilotumumab) with panitumumab in previously treated patients with wild-type KRAS mCRC.|
|Internal ID Number:||24919569|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.